Validation of prognostic scores for survival in cancer patients beyond first-line therapy

BMC Cancer

Table 3 Prognostic parameters on univariate analysis

	Univariate analysis
	HR	95% CI	p value
ECOG Performance Status
0-1
> 1	2.95	[2.27-3.84]	< .0001
Platelet count (G/L)
≥130
< 130	2.67	[1.83-3.88]	< .0001
CRP (mg/L)
≤10
> 10	2.25	[1.67-3.04]	< .0001
LDH (U/L)
≤600
> 600	2.17	[1.64-2.88]	< .0001
IL-6 (pg/mL)
≤8
> 8	2.16	[1.66-2.81]	< .0001
Albumin (g/L)
≥38
< 38	2.12	[1.56-2.89]	< .0001
Hemoglobin
Normal
Abnormal†	1.88	[1.46-2.43]	< .0001
Weight loss >10% (in the past 6 months)
No
Yes	1.83	[1.37-2.45]	< .0001
Lymphocyte count
> 700/μL
≤700/μL	1.80	[1.39-2.33]	< .0001
VEGF (pg/mL)
≤755
> 755	1.55	[1.15-2.09]	0.0044
Number of metastatic sites
≤2
> 2	1.50	[1.14-1.99]	0.0042
Quality of life using 0-10 VAS
≥5
< 5	1.53	[1.18-1.98]	0.0012
Absolute neutrophil count
≥2
< 2	1.30	[0.78-2.16]	0.3
Liver metastases
No
Yes	1.19	[0.93-1.53]	0.16
Age (years)
≤60
> 60	0.97	[0.76-1.23]	0.8
Previous adjuvant chemotherapy
No
Yes	0.91	[0.71-1.18]	0.5

LDH: lactate dehydrogenase; CRP: C-reactive protein; IL-6: interleukin 6; VEGF: Vascular Endothelial Growth Factor; VAS: visual analog scale.
† < 11.5 g/dL for women, <13.0 g/dL for men

ISSN: 1471-2407